Listing 13.21 Kidney, Adrenal, Ureter, and Bladder Cancer in 2026
Kidney cancer and bladder cancer together account for a large share of US cancer burden. The American Cancer Society projects 82,000 new kidney/renal pelvis cancer cases (52,380 men, 29,620 women) with 14,860 deaths in 2026. Urinary bladder cancer projects 83,000 new cases (63,070 men, 19,930 women) with 17,100 deaths. Ureter and adrenal cancers are rarer but included in the same SSA listing.
SSA Listing 13.21 covers all these urinary tract malignancies in one section with three paragraphs. Inoperable or unresectable primary tumors, recurrent disease, and metastatic disease all qualify. This walkthrough covers histologic subtypes, the modern treatment landscape (immunotherapy for RCC and urothelial cancer, targeted therapy, enfortumab vedotin + pembrolizumab first-line for advanced urothelial), and the surgical residuals that dominate CDR for patients who reach the 3-year mark.
See If You Qualify
The listing text
Paragraph A: Inoperable, unresectable, or extending beyond the primary organ
Primary cancer that is inoperable, unresectable, or has extended locally beyond the organ of origin meets Paragraph A. For kidney cancer this includes tumors invading Gerota's fascia, ipsilateral adrenal gland with contiguous extension, or extending into renal vein or inferior vena cava with tumor thrombus. For bladder cancer this includes T4 disease invading prostate, uterus, vagina, pelvic sidewall, or abdominal wall (locally advanced, often T4b unresectable).
Paragraph B: Recurrent disease
Recurrent kidney, adrenal, ureter, or bladder cancer after prior treatment qualifies under Paragraph B. Recurrence rates vary by stage and histology - about 20-40% of localized RCC recurs after nephrectomy within 5 years, and about 40-70% of muscle-invasive bladder cancer recurs after cystectomy.
Paragraph C: Metastases to or beyond regional lymph nodes
Metastases to regional nodes:
- Kidney - hilar, retroperitoneal, para-aortic, paracaval nodes
- Bladder - true pelvis nodes (perivesical, obturator, internal iliac, external iliac, common iliac)
- Ureter - regional nodes depending on ureteral segment
- Adrenal - para-aortic, paracaval, retroperitoneal nodes
Distant metastases (beyond regional nodes) also qualify. Common sites for kidney cancer: lung (75%), bone (30-40%), liver, brain. Urothelial bladder cancer: lung, liver, bone.
Renal cell carcinoma subtypes
Clear cell RCC (75% of adult kidney cancer)
Most common subtype. Driven by VHL gene loss on chromosome 3p. Highly vascular tumor. Sensitive to anti-angiogenic therapy (VEGF pathway) and immunotherapy. Better response to systemic therapy than non-clear cell subtypes. Median OS for metastatic ccRCC has improved from about 12 months (interferon era) to 40+ months with modern combination therapy.
Papillary RCC (10-15%)
Two subtypes: Type 1 (basophilic, less aggressive, often MET-driven) and Type 2 (eosinophilic, more aggressive, heterogeneous molecular drivers). Less responsive to VEGF/immunotherapy than ccRCC. MET inhibitors (savolitinib, crizotinib) show activity in MET-altered pRCC.
Chromophobe RCC (5%)
Better prognosis than ccRCC. Loss of multiple chromosomes. Less responsive to typical RCC therapies. Sarcomatoid transformation possible with aggressive behavior.
Collecting duct carcinoma / renal medullary carcinoma (rare)
Aggressive subtypes with poor prognosis. Renal medullary carcinoma occurs almost exclusively in patients with sickle cell trait/disease and is nearly universally metastatic at diagnosis.
Sarcomatoid features
Not a distinct subtype but a marker of aggressive behavior. Can occur in any histologic subtype. Sarcomatoid RCC responds better to immunotherapy than to VEGF inhibitors.
Urothelial (bladder) cancer subtypes
Non-muscle-invasive bladder cancer (NMIBC, 75% of new bladder cancer)
Includes carcinoma in situ (CIS), Ta (non-invasive papillary), T1 (invades subepithelial connective tissue). Treated with transurethral resection (TURBT) + intravesical BCG or chemotherapy. Progression to muscle-invasive disease occurs in about 20% of high-risk NMIBC. NMIBC alone generally does not meet 13.21 unless it becomes muscle-invasive, recurrent, or requires cystectomy.
Muscle-invasive bladder cancer (MIBC, 25% at diagnosis)
T2 (invades muscularis propria) and beyond. Standard treatment: neoadjuvant cisplatin-based chemotherapy + radical cystectomy or trimodal therapy (TURBT + chemo + radiation). Muscle-invasive disease alone generally meets 13.21 through inoperable disease (T4b), regional nodal involvement, distant metastases, or recurrence.
Metastatic urothelial cancer
Distant disease. First-line therapy shifted 2024 to enfortumab vedotin + pembrolizumab (EV-302 trial) as new standard.
Variant histologies
Squamous cell carcinoma of bladder, adenocarcinoma, small cell/neuroendocrine, plasmacytoid, micropapillary, sarcomatoid. Small cell bladder cancer behaves like small cell lung cancer with aggressive chemotherapy required.
Diagnostic evidence required
SSA requires objective medical evidence:
- Pathology report: histologic subtype, grade (Fuhrman/WHO/ISUP for RCC, WHO for urothelial), TNM staging, margin status, lymphovascular invasion, presence of sarcomatoid or rhabdoid features
- Cross-sectional imaging: CT abdomen/pelvis with contrast, MRI abdomen for renal tumor characterization, CT chest for lung mets, bone scan or PET-CT for staging
- Renal function: creatinine, eGFR, 24-hour urine studies
- Urine cytology for urothelial cancer surveillance
- Cystoscopy and TURBT pathology for bladder cancer
- Molecular testing:
- RCC: no routine actionable mutations, but VHL status if familial suspected. PD-L1 not required. HIF-2 alpha targeting (belzutifan) approved 2023 for VHL-associated tumors.
- Urothelial: FGFR2/3 mutations/fusions (15-20% of metastatic, erdafitinib targeted therapy), HER2 (trastuzumab deruxtecan approved), Nectin-4 (target of enfortumab vedotin, essentially all urothelial cancers express)
- Oncology consultation notes with stage and treatment plan
The Compassionate Allowance overlay
Kidney cancer with distant metastases and stage IV urothelial cancer are on the CAL list. Non-metastatic kidney or bladder cancers meeting 13.21 through inoperable status or regional nodal involvement go through standard SSDI processing.
Modern treatment residuals for the CDR
Immunotherapy combinations for RCC
Standard first-line for advanced clear cell RCC as of 2026:
- Nivolumab + cabozantinib (CheckMate 9ER)
- Pembrolizumab + axitinib (KEYNOTE-426)
- Pembrolizumab + lenvatinib (CLEAR)
- Nivolumab + ipilimumab (CheckMate 214, particularly for intermediate/poor risk)
- Pembrolizumab monotherapy (adjuvant KEYNOTE-564 for high-risk resected)
Toxicities: checkpoint inhibitor irAEs (colitis, hepatitis, pneumonitis, endocrine dysfunction) plus TKI toxicities (hypertension, hand-foot syndrome, diarrhea, hypothyroidism from TKI, proteinuria).
Belzutifan (HIF-2 alpha inhibitor)
Approved 2021 for VHL-associated tumors and 2023 for advanced ccRCC after prior IO/TKI. Toxicities: anemia (severe, requires monitoring), hypoxia, fatigue.
Immunotherapy + antibody-drug conjugate for urothelial
Enfortumab vedotin (Nectin-4 targeted ADC with MMAE payload) + pembrolizumab became first-line 2024 for metastatic urothelial per EV-302 trial. Toxicities:
- Peripheral neuropathy from MMAE (40-50%, can be permanent)
- Skin reactions including severe cutaneous adverse reactions
- Hyperglycemia
- Ocular disorders
- Pneumonitis (from pembrolizumab)
- Endocrine irAEs (hypothyroidism most common)
Erdafitinib
FGFR inhibitor for FGFR3/2-altered metastatic urothelial. Toxicities: hyperphosphatemia (universal), central serous retinopathy, dry mouth, nail changes.
Radical nephrectomy or partial nephrectomy
Partial nephrectomy preferred when feasible for smaller tumors to preserve renal function. Radical nephrectomy standard for larger or infiltrative tumors. Residuals:
- Chronic kidney disease (about 30% develop CKD stage 3 or worse post-radical nephrectomy)
- Renal insufficiency-related fatigue, anemia
- Ipsilateral adrenal insufficiency if adrenalectomy performed
- Chronic incisional pain
Radical cystectomy with urinary diversion
Standard for muscle-invasive bladder cancer. Removal of bladder plus prostate/seminal vesicles in men or bladder + uterus + ovaries + anterior vaginal wall in women. Urinary diversion options:
- Ileal conduit (external stoma with bag) - simpler, faster recovery, requires ongoing stoma care
- Continent cutaneous reservoir (catheterizable stoma)
- Orthotopic neobladder (fashioned from ileum, connected to urethra)
Universal residuals: sexual dysfunction (near-universal in men, high in women), impaired body image, need for ostomy care or neobladder training, chronic risk of urinary tract infection, metabolic acidosis (chronic), vitamin B12 deficiency (from terminal ileum resection), chronic diarrhea, bowel obstruction from adhesions.
Worked case examples
Case 1: Robert, 62, Ohio, stage IV clear cell RCC with lung metastases
Robert presented with hematuria and 20 lb weight loss in January 2026. CT abdomen: 8 cm left renal mass with tumor thrombus into left renal vein. CT chest: 4 lung nodules up to 2 cm. Biopsy: clear cell RCC, IMDC intermediate risk. Started cabozantinib + nivolumab per CheckMate 9ER.
SSDI application filed February 2026. CAL for metastatic RCC triggered. Approved 10 days at Ohio DDS. Partial response at 3 months. Developed grade 3 hepatitis at month 6 from checkpoint inhibitor, permanent nivolumab discontinuation, continued cabozantinib. Autoimmune hypothyroidism (permanent, levothyroxine).
Case 2: Angela, 67, New York, muscle-invasive urothelial bladder cancer post-radical cystectomy
Angela presented with painless hematuria in March 2026. Cystoscopy + TURBT: high-grade muscle-invasive urothelial carcinoma T2. Received neoadjuvant dose-dense MVAC chemotherapy, then radical cystectomy + bilateral pelvic lymphadenectomy + ileal conduit urinary diversion. Final pathology: pT3N1 with 3 of 22 positive nodes.
SSDI application filed October 2026 (post-cystectomy). Listing 13.21C met (regional nodal metastases). Approved 4 weeks at New York DDS. Adjuvant nivolumab per CheckMate 274. Ongoing at 6-month follow-up. Chronic ileal conduit with ostomy care, chronic metabolic acidosis, B12 supplementation, chronic UTI prophylaxis.
Case 3: Michael, 71, Texas, metastatic urothelial cancer on enfortumab vedotin + pembrolizumab
Michael was diagnosed with muscle-invasive bladder cancer 2023, treated with cystectomy + ileal conduit. Surveillance CT January 2026 showed 3 new liver lesions and retroperitoneal nodes. Biopsy: metastatic urothelial carcinoma. Started enfortumab vedotin + pembrolizumab per EV-302.
SSDI application filed February 2026. Listing 13.21B (recurrent) and 13.21C (metastatic) met. CAL for stage IV urothelial. Approved 12 days at Texas DDS. Partial response at 3 months. Developed grade 2 peripheral neuropathy from MMAE, dose reduction. Also developed hyperglycemia requiring metformin.
What to file with your application
- Pathology report with histologic subtype, grade, TNM staging
- Cross-sectional imaging (CT abdomen/pelvis, CT chest, PET-CT if available)
- Cystoscopy and TURBT report for bladder cancer
- Renal function panel (creatinine, eGFR)
- Urine cytology for urothelial disease
- Molecular testing (FGFR3/2 for urothelial, HER2, PD-L1)
- Post-operative pathology if surgery performed
- Oncology consultation notes with stage assignment and treatment plan
- Documentation of any recurrence with imaging comparison
Free eligibility review in 60 seconds.
See If You Qualify
Related reading
Full section walkthrough: Section 13.00 cancer basics. Related listings: 6.04 kidney transplantation for post-nephrectomy CKD cases. Other cancer listings: 13.24 prostate, 13.18 colorectal, 13.19 liver.
Frequently asked questions
Does every kidney cancer qualify for SSDI?
No. Small localized kidney cancers (T1a under 4 cm) treated by partial nephrectomy with negative margins and no nodal or distant disease typically do not meet 13.21. Once disease is inoperable, recurrent, or has spread to nodes or distant sites, Listing 13.21 is met.
What about non-muscle-invasive bladder cancer?
NMIBC (Ta, T1, CIS) treated with TURBT + BCG generally does not meet 13.21. Progression to muscle-invasive, recurrent MIBC after initial treatment, or metastatic disease qualifies.
What are the CAL triggers for kidney and bladder cancer?
Kidney cancer with distant metastases and stage IV urothelial cancer are on the CAL list. These trigger 14-30 day expedited processing.
Does BCG treatment for bladder cancer support disability?
BCG alone for NMIBC does not meet 13.21. However, BCG side effects (chronic cystitis, systemic BCG reaction, disseminated BCG) can create functional limitations that may support RFC-based analysis.
What is the difference between ileal conduit and neobladder?
Ileal conduit uses a segment of ileum to create an external stoma draining into a bag. Simpler surgery, faster recovery, requires ongoing stoma care. Orthotopic neobladder fashions ileum into a reservoir connected to the urethra, allowing continence but requiring intermittent self-catheterization and neobladder training.
Can I qualify for SSDI after radical nephrectomy?
Depends on staging. If disease was localized T1-T2 without nodal involvement and margins are negative, you may not meet 13.21 (though the surgery may still qualify through Listing 6.03/6.04 if CKD develops). Positive nodes, positive margins, inoperable primary, or metastatic disease meets 13.21.
What is IMDC risk stratification?
International Metastatic RCC Database Consortium risk score. Uses 6 factors (Karnofsky under 80%, time from diagnosis to treatment under 1 year, anemia, hypercalcemia, neutrophilia, thrombocytosis) to stratify metastatic RCC into favorable (0 factors), intermediate (1-2), and poor (3+) risk. Drives treatment selection and prognosis.
Next steps
If you were diagnosed with inoperable or metastatic kidney, adrenal, ureter, or bladder cancer, file for SSDI immediately after pathology confirmation. CAL fast-track applies to metastatic RCC and stage IV urothelial disease.